Allison Dorval, serving as a director at PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI), has executed a significant transaction involving the company's common stock. On June 12, 2026, Dorval sold 11,610 shares, generating a total transaction value of $83,579. The liquidation of these shares occurred at prices fluctuating between $6.98 and $7.32 per share. This specific sale was facilitated through a pre-arranged 10b5-1 trading plan, a mechanism designed to allow executives to trade company stock without the appearance of insider trading, which Dorval originally adopted on March 12, 2025.
The timing of this sale is notable given the current market performance of PBYI. The stock was trading at $7.09 at the time of the report, a figure that sits close to its 52-week high of $7.90. This price point reflects a substantial 105% gain for the stock over the past year, indicating a period of significant appreciation for shareholders. Despite the recent sales, Dorval's direct holdings in the company remain substantial. Following the execution of these transactions, she continues to hold 90,780 shares of PUMA BIOTECHNOLOGY, INC. common stock directly.
On the day prior to the sale, June 11, 2026, Dorval also engaged in a significant acquisition activity. She acquired 27,000 shares of common stock, which are classified as Restricted Stock Units (RSUs). These specific units are structured to vest in full upon the earlier of two events: the one-year anniversary of the grant date or the date of the annual shareholder meeting following the grant date. This vesting is strictly contingent upon her continued service with the Issuer, aligning her long-term incentives with the company's operational continuity.
The insider activity occurs concurrently with a period of financial scrutiny for Puma Biotechnology Inc. The company recently reported its first-quarter 2026 earnings, a period that did not align with analyst projections. The financial report highlighted a net loss per share of -$0.04, a figure that fell short of the anticipated $0.00. Furthermore, revenue for the quarter was recorded at $44.8 million, which was below the expected $49 million. This discrepancy resulted in a revenue surprise of -8.57%, marking a challenging quarter for the biotech firm.
These financial results have highlighted investor concerns regarding the company's financial performance. While analysts had forecasted more positive outcomes, the actual figures indicate specific areas where the company did not meet projections. These developments are crucial for investors monitoring Puma Biotechnology's financial health and market position, particularly as the stock has seen a remarkable 105% gain over the past year. The contrast between the stock's market performance and the missed earnings expectations underscores the complexity of the current investment landscape for PBYI.